Reddit is a popular place for people to talk openly about personal experiences with medications, including both positive outcomes and concerns
After tirzepatide was approved for marketing in the United States in 2022, the number of prescriptions has continued to grow rapidly, and the growth rate far exceeds that of semaglutide during the same period, driving the rapid increase of tirzepatide's market share
Insurance coverage for GLP-1 medications like Ozempic has become increasingly restrictive, with most major carriers including Aetna limiting approval to patients with diagnosed type 2 diabetes rather than obesity alone
G., Assmus, C., Maisonneuve, P
Some authors have raised concerns about a possible increased risk of NAION 5,8 with GLP-1 RA use, while other studies demonstrated no statistical differences between cohorts
The Journal of endocrinology 204 , 93104, doi: 10.1677/JOE-09-0359 (2010)